Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06828588 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Feb 2026 to Apr 16, 2026 · Site details revisedv9 Show 2 more changesShow less
    • Start date changed from estimate of Feb 2026 to Apr 16, 2026
    • Site details revised
  2. Interventions: ABY-025 Loading Dose (Drug), [68Ga]Ga-ABY-025 (Drug) to [68Ga]Ga-ABY-025 (Drug) Study description shortened, about 4 wordsv8 Show 1 more changeShow less
    • Study description shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  3. Start date: Nov 2025 to Feb 2026v7
  4. Primary endpoint revisedv6 See this version in full on ClinicalTrials.gov ↗
  5. Primary endpoint revised Start date: Oct 2025 to Nov 2025 · Eligibility criteria expanded, about 18 wordsv5 Show 2 more changesShow less
    • Start date: Oct 2025 to Nov 2025
    • Eligibility criteria expanded, about 18 words

    See this version in full on ClinicalTrials.gov ↗

Show 3 earlier versionsHide 3 earlier versions
  1. Start date: May 2025 to Oct 2025v4
  2. Start date: Feb 2025 to May 2025v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Vanderbilt-Ingram Cancer Center
45 trials monitored
See 3 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Head & Neck Cancer
2,060 trials monitored
See 120 trials at risk
Gastric Cancer
1,201 trials monitored
See 59 trials at risk
and 1 more disease
The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.
Trial Details
NCT Number NCT06828588
Lead Sponsor Vanderbilt-Ingram Cancer Center
Conditions Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov